HC Wainwright Reaffirms “Neutral” Rating for 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a research note issued on Monday,Benzinga reports.

60 Degrees Pharmaceuticals Stock Performance

60 Degrees Pharmaceuticals stock traded down $0.10 during midday trading on Monday, reaching $1.16. 1,430,861 shares of the company’s stock were exchanged, compared to its average volume of 286,002. The stock’s 50-day simple moving average is $1.09 and its 200 day simple moving average is $0.90. The firm has a market cap of $2.66 million, a price-to-earnings ratio of -0.12 and a beta of 5.36. 60 Degrees Pharmaceuticals has a 52 week low of $0.70 and a 52 week high of $18.36.

Insider Transactions at 60 Degrees Pharmaceuticals

In related news, CEO Geoffrey S. Dow bought 35,823 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was bought at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the purchase, the chief executive officer now owns 94,580 shares in the company, valued at $120,116.60. This represents a 60.97 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders acquired 66,372 shares of company stock worth $82,410. 10.27% of the stock is owned by company insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.